Tuesday, September 2, 2014

Knight to acquire rights to ATryn, Photofrin

Knight to acquire rights to ATryn, Photofrin

September 2, 2014 by · Leave a Comment 

Tweet Knight Therapeutics (TSX:GUD) has entered into an asset purchase agreement with closely-held Orphan Canada for the Canadian rights to ATryn and Photofrin, two innovative pharmaceutical products approved for sale in multiple jurisdictions. As part of the agreement, Jason Flowerday and Joost van der Mark, the co-founders of Orphan, will join the Knight, with Mr. […]

Amarantus initiates CLIA development of AZ test

Amarantus initiates CLIA development of AZ test

September 2, 2014 by · Leave a Comment 

Tweet Amarantus Bioscience Holdings (OTCQB:AMBS) has entered into a master services agreement with ICON for global therapeutic and diagnostic clinical development services. Amarantus has submitted an initial work order to ICON for delivery of the Fit for Purpose Flow Cytometry Assay Validation of the company’s flagship Alzheimer’s disease blood diagnostic, LymPro Test, at ICON’s CLIA-certified […]

Stifel starts Loxo Oncology at buy

Stifel starts Loxo Oncology at buy

September 2, 2014 by · Leave a Comment 

Tweet Stifel has launched coverage of Loxo Oncology (NASDAQ:LOXO) with a “buy” rating and 12-month price target of $20. The stock closed at $13.01 on Friday. “We believe Loxo is poised to become an emerging leader in the discovery/development of targeted small molecule therapeutics for the treatment of genetically-defined cancers,” writes analyst Stephen Willey. He […]

Novadaq names Robert White to its board

Novadaq names Robert White to its board

September 2, 2014 by · Leave a Comment 

Tweet Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has appointed Robert White to its board. Mr. White is a medical technology industry veteran with over 25 years of high-level experience gained through numerous leadership positions with Medtronic, Instromedix-LifeWatch, ALARIS Medical Systems, Eli Lilly and General Electric. He was most recently president and CEO of TYRX, a closely-held company […]

Leerink starts T2 Biosystems at market perform

Leerink starts T2 Biosystems at market perform

September 2, 2014 by · Leave a Comment 

Tweet Leerink Partners has initiated coverage of T2 Biosystems (NASDAQ:TTOO) with a “market perform” rating and price target of $23.50. The stock closed at $23.21 on Friday. “While we are compelled by T2’s value proposition in potentially large markets with high unmet need, we consider its current stock price and premium multiple to fairly balance […]

Leerink starts Auris Medical at outperform

Leerink starts Auris Medical at outperform

August 31, 2014 by · Leave a Comment 

Tweet Leerink Partners has initiated coverage of Auris Medical Holding AG (NASDAQ:EARS) with an “outperform” rating and 12-month price target of $10. The stock closed at $6.15 on Friday. Auris is a first-mover focused on developing products in untapped otology markets, including tinnitus, or a ringing in the ears, and hearing loss. “Auris’ lead product […]

Lorus changing name to Aptose Biosciences

Lorus changing name to Aptose Biosciences

August 31, 2014 by · Leave a Comment 

Tweet Lorus Therapeutics (OTC:LRUSF; TSX:LOR) has changed its name to Aptose Biosciences and its trading symbol to APS, according to the Toronto Stock Exchange. The TSX reports the company’s shares will start trading under the new name and symbol at the opening on Sept. 3.

Response Biomedical names Shuster chairman

Response Biomedical names Shuster chairman

August 29, 2014 by · Leave a Comment 

Tweet Response Biomedical (OTCBB:RPBIF; TSX:RBM) has named Lewis (Lew) Shuster as chairman of its board, replacing Dr. Peter Thompson, who will continue as a director. “Lew brings more than three decades of global life science company executive and board leadership experience to Response,” Dr. Thompson said in a statement. “He has made valuable contributions since joining […]

Amarantus appoints Iain Ross to board

Amarantus appoints Iain Ross to board

August 29, 2014 by · Leave a Comment 

Tweet Amarantus Bioscience Holdings (OTCQB:AMBS) has appointed Iain Ross to its board of directors. Mr. Ross brings over 30 years of biopharmaceutical industry experience to Amarantus across executive management, investment and directorship roles. “Mr. Ross has an extensive background in biologic drug development, and strategic corporate transactions that have led to significant accretion of shareholder […]

Knight adds to management, Board

Knight adds to management, Board

August 26, 2014 by · Leave a Comment 

Tweet Knight Therapeutics (TSX:GUD) has appointed Amal Khouri to the position of VP of business development and Sylvie Tendler to its Board. “Both Amal and Sylvie are proven pharmaceutical executives and expand our capacity to secure the rights to innovative pharmaceuticals that improve the health of Canadians,” Jonathan Ross Goodman, president and CEO, said in […]

Next Page »

Email Newsletters with Constant Contact
Google+